Friday, August 22, 2014 8:51:55 AM
"LANSING, MI--(Marketwire - May 31, 2011) - Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that it successfully mated its transgenic silkworms, which produce recombinant spider silk, with a physically larger commercial strain of the domesticated silkworm. The resulting hybrid silkworms are larger than Kraig's original transgenic silkworms and are also producing significantly larger recombinant silk cocoons.
Independent laboratory testing confirmed that the transgenic/commercial silkworm hybrids are producing silk which is significantly stronger and more flexible than that of the original commercial strain. The new recombinant spider silk is a composite silk composed of both native silkworm silk proteins and spider silk proteins (as in the original Kraig transgenic silkworm whose development was announced in late September).
Kim Thompson, the Company's CEO and Founder, stated, "The new hybrid was specifically designed for commercialization and has been designated 'Monster Hybrid,' which is the successful cross between our transgenic silkworms and a much larger commercial strain.
"The result is a large, robust, commercial sized silkworm which spins a larger commercial sized cocoon composed of recombinant spider silk like the original transgenic. The new hybrid was specifically designed to generate greater recombinant silk production capacity than our original first generation transgenic."
"This larger hybrid transgenic will be the platform for our commercialization ramp up," Thompson continued. "Now that the strength and elasticity qualities have been confirmed, we can move forward with cultivating the hybrids in commercially viable quantities. We are working diligently to increase our stock of the new strain in order to increase our production capacity."
over 3 years ago....and counting
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM